KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Other Operating Expenses (2019 - 2025)

Royalty Pharma's Other Operating Expenses history spans 7 years, with the latest figure at $18.8 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses fell 88.52% year-over-year to $18.8 million; the TTM value through Dec 2025 reached -$206.8 million, down 128.23%, while the annual FY2025 figure was -$206.8 million, 128.23% down from the prior year.
  • Other Operating Expenses for Q4 2025 was $18.8 million at Royalty Pharma, up from -$37.6 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $924.7 million in Q4 2022 and bottomed at -$238.0 million in Q2 2021.
  • The 5-year median for Other Operating Expenses is $153.8 million (2021), against an average of $154.4 million.
  • The largest YoY upside for Other Operating Expenses was 613.05% in 2021 against a maximum downside of 549.02% in 2021.
  • A 5-year view of Other Operating Expenses shows it stood at $272.3 million in 2021, then soared by 239.58% to $924.7 million in 2022, then tumbled by 108.27% to -$76.5 million in 2023, then surged by 314.39% to $164.0 million in 2024, then crashed by 88.52% to $18.8 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Other Operating Expenses are $18.8 million (Q4 2025), -$37.6 million (Q3 2025), and -$60.9 million (Q2 2025).